Chronic Lymphocytic Leukemia (CLL)
Conditions
Keywords
chronic lymphocytic leukemia, IRAK4
Brief summary
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).
Detailed description
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC). Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.
Interventions
PROCEDUREPeripheral blood sample collection
Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.
Sponsors
IRCCS San Raffaele
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Diagnosis of CLL * Participant is willing and able to give informed consent for participation in the study.
Exclusion criteria
\- Participant is unable or unwilling to provide informed consent for participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TLR signaling | 12 months | In vitro inhibition of TLR signaling in CLL cells following exposure to IRAK4 CDAC, as assessed by modulation of downstream signaling molecules (e.g. phosphorylation status and/or degradation of key components of the TLR pathway). |
Contacts
CONTACTPaolo Ghia, MD, PhD
CONTACTLydia Scarfo, MD
Outcome results
None listed